CheckMate 816试验：非小细胞肺癌新辅助化疗免疫疗法的一个里程碑。
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.
作者信息
Mayenga Marie, Pedroso Ana Rita, Ferreira Marion, Gille Thomas, Pereira Catarata Maria Joana, Duchemann Boris
机构信息
Department of Pulmonology, Foch Hospital, Suresnes, France.
Pulmonology Department, Local Health Unit of Braga, Braga, Portugal.
出版信息
Breathe (Sheff). 2024 Nov 12;20(3):240044. doi: 10.1183/20734735.0044-2024. eCollection 2024 Oct.
Abstract
Advancements in immunotherapy in the perioperative setting have revolutionised the treatment of resectable nonsmall cell lung cancer (NSCLC). Here we present the methodology and results of the clinical trial CheckMate 816 demonstrating the benefit of neoadjuvant therapy with nivolumab plus chemotherapy compared with chemotherapy alone. Furthermore, this article discusses the implications for future practice in resectable NSCLC and the need for future research.
摘要
围手术期免疫治疗的进展彻底改变了可切除非小细胞肺癌（NSCLC）的治疗方式。在此，我们介绍了CheckMate 816临床试验的方法和结果，该试验证明了与单纯化疗相比，纳武利尤单抗联合化疗进行新辅助治疗的益处。此外，本文还讨论了其对可切除NSCLC未来临床实践的影响以及未来研究的必要性。
相似文献
1
The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer.CheckMate 816试验：非小细胞肺癌新辅助化疗免疫疗法的一个里程碑。
Breathe (Sheff). 2024 Nov 12;20(3):240044. doi: 10.1183/20734735.0044-2024. eCollection 2024 Oct.
2
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC.Checkmate 77T：围手术期化疗免疫治疗在早期 NSCLC 中表现更佳。
Med. 2024 Aug 9;5(8):852-855. doi: 10.1016/j.medj.2024.06.012.
3
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.纳武利尤单抗联合化疗对比化疗用于可切除 NSCLC 患者的新辅助治疗：CheckMate 816 研究中中国患者的亚组分析。
ESMO Open. 2023 Dec;8(6):102040. doi: 10.1016/j.esmoop.2023.102040. Epub 2023 Nov 1.
4
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer.可切除非小细胞肺癌的新辅助免疫疗法
Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163798. doi: 10.1177/17588359231163798. eCollection 2023.
5
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.CheckMate 816 研究中可切除的非小细胞肺癌日本患者中纳武利尤单抗联合化疗的新辅助治疗。
Cancer Sci. 2024 Feb;115(2):540-554. doi: 10.1111/cas.16030. Epub 2023 Dec 14.
6
[Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].新辅助化疗免疫疗法在可切除非小细胞肺癌中的应用
Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):822-832. doi: 10.3779/j.issn.1009-3419.2023.102.40.
7
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
8
The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.非小细胞肺癌围手术期治疗的新兴模式：一项叙述性综述
Chin Clin Oncol. 2024 Feb;13(1):12. doi: 10.21037/cco-23-137. Epub 2024 Feb 5.
9
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.新辅助化疗免疫治疗可切除 NSCLC 患者完全病理缓解和疾病进展相关的肿瘤微环境基因表达谱。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005320.
10
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.免疫疗法在可切除非小细胞肺癌中的新作用。
Ann Thorac Surg. 2024 Jul;118(1):119-129. doi: 10.1016/j.athoracsur.2024.01.024. Epub 2024 Feb 3.
本文引用的文献
1
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.MDT-BRIDGE：可切除或边缘可切除的 IIB-IIIB 期 NSCLC 患者中，新辅助度伐利尤单抗联合化疗，然后手术联合辅助度伐利尤单抗，或放化疗联合巩固性度伐利尤单抗。
Clin Lung Cancer. 2024 Sep;25(6):587-593.e3. doi: 10.1016/j.cllc.2024.06.007. Epub 2024 Jun 21.
2
Moving Immunotherapy Into the Treatment of Resectable Non-Small Cell Lung Cancer.将免疫疗法应用于可切除的非小细胞肺癌的治疗中。
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432500. doi: 10.1200/EDBK_432500.
3
Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.新辅助化疗免疫治疗早期非小细胞肺癌：系统评价和荟萃分析。
JAMA Netw Open. 2024 Apr 1;7(4):e246837. doi: 10.1001/jamanetworkopen.2024.6837.
4
Enhancing Patient Selection in Stage IIIA-IIIB NSCLC: Invasive Lymph Node Restaging after Neoadjuvant Therapy.优化ⅢA-ⅢB期非小细胞肺癌患者的选择：新辅助治疗后的侵袭性淋巴结再分期
J Clin Med. 2024 Jan 12;13(2):422. doi: 10.3390/jcm13020422.
5
Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.新辅助联合免疫治疗可切除癌症患者的不良事件：系统评价和荟萃分析。
Front Immunol. 2024 Jan 5;14:1269067. doi: 10.3389/fimmu.2023.1269067. eCollection 2023.
6
Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection.接受完全手术切除的非小细胞肺癌患者的基因改变与复发风险因素
Cancers (Basel). 2023 Nov 30;15(23):5679. doi: 10.3390/cancers15235679.
7
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.可切除 NSCLC 中围手术期或新辅助免疫检查点抑制剂联合铂类化疗的手术和生存结果：随机临床试验的系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21.
8
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.阿特珠单抗辅助化疗用于可切除 II-IIIA 期非小细胞肺癌的总生存期：一项随机、多中心、开放标签、III 期试验（IMpower010）。
Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17.
9
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.III 期非小细胞肺癌的围手术期纳武利尤单抗和化疗。
N Engl J Med. 2023 Aug 10;389(6):504-513. doi: 10.1056/NEJMoa2215530. Epub 2023 Jun 28.
10
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
Zotero 插件